Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by ChaseYourDreamon Jan 09, 2017 6:51pm
131 Views
Post# 25685634

RE:Any Contact?

RE:Any Contact?Others have argued, and I agree, that no NR is necessary as the trials proceed, since they have already NR's that they are in process.

The pattern has been not to NR every nuance, and I thnk it is good dicipline for many reasons. Not just trading ethics, but also medical ethics, and in science you don't publish until you have the stat ewvidence to back up yout conclusions.

But since the expectation of three test patients is certain, a poliute request is Roger can share that, via email or phone, might be welcomed and even obliged with an answer. I suggest asking respectfully at what stage inthe prodcfess heanticipotaed releasing an NR, and (with the trend positive), you can graciously let slip that "we'd love to know that all three are enrolled, whenever that happens."

Roger may have replied to me because he was looking for subscribers, but I respect him too much to think that was the only reason. The conversation was substantive and well-managed on his end.

I hope you email him. Good luck. CYD





toade1313 wrote: Does anyone know when RW plans to do a PR? My guess is that once all 3 patients have been approved, that would be a 'material event' that should be disclosed in a PR. I admit this is just speculation on my part. I know some of you have in the past have had email and/or phone contacts with the company and I wonder if this topic had come up? Obviously I know RW couldn't give a specific date, but he could indicate when _____ events have occured he would issue a PR. Thx for any info you have and are authorized to pass on.


Bullboard Posts